Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), Avanos Medical (AVNS) and 10x Genomics (TXG)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKSResearch Report), Avanos Medical (AVNSResearch Report) and 10x Genomics (TXGResearch Report).

Alkermes (ALKS)

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Alkermes on November 4 and set a price target of $27.00. The company’s shares closed last Monday at $23.32.

According to TipRanks.com, Matteis is a 4-star analyst with an average return of 7.3% and a 45.0% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, KalVista Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Alkermes is a Moderate Buy with an average price target of $30.25, which is a 26.7% upside from current levels. In a report issued on November 3, H.C. Wainwright also maintained a Hold rating on the stock with a $32.00 price target.

See the top stocks recommended by analysts >>

Avanos Medical (AVNS)

In a report issued on November 4, Rick Wise from Stifel Nicolaus maintained a Hold rating on Avanos Medical, with a price target of $25.00. The company’s shares closed last Monday at $24.04.

According to TipRanks.com, Wise is a 4-star analyst with an average return of 5.5% and a 56.7% success rate. Wise covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Edwards Lifesciences, and Baxter International.

Currently, the analyst consensus on Avanos Medical is a Hold with an average price target of $29.67, which is a 28.3% upside from current levels. In a report issued on November 3, JMP Securities also reiterated a Hold rating on the stock.

10x Genomics (TXG)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on 10x Genomics on November 4 and set a price target of $53.00. The company’s shares closed last Monday at $30.90, close to its 52-week low of $23.81.

According to TipRanks.com, Arias is a 1-star analyst with an average return of -1.5% and a 47.3% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, NanoString Tech, and Guardant Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 10x Genomics with a $52.33 average price target, which is a 64.6% upside from current levels. In a report issued on November 3, J.P. Morgan also maintained a Buy rating on the stock with a $55.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALKS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More